The first in a two-part series, this 0.50-credit, 30-minute CME multiplatform program discusses the importance of early identification of AD and how to detect it early, the pathobiology of AD and potential treatments in development to target this pathology, and current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment.